Department of Pharmacy, Pharmaceutical Technology & Physical Chemistry, Faculty of Pharmacy & Food Sciences, University of Barcelona, Barcelona, Spain.
Institute of Nanoscience & Nanotechnology (IN2UB), Barcelona, Spain.
Nanomedicine (Lond). 2021 Jan;16(1):19-35. doi: 10.2217/nnm-2020-0239. Epub 2021 Jan 7.
To compare free and nanoparticle (NP)-encapsulated epigallocatechin-3-gallate (EGCG) for the treatment of Huntington's disease (HD)-like symptoms in mice. EGCG was incorporated into PEGylated poly(lactic-co-glycolic) acid NPs with ascorbic acid (AA). HD-like striatal lesions and motor deficit were induced in mice by 3-nitropropionic acid-intoxication. EGCG and EGCG/AA NPs were co-administered and behavioral motor assessments and striatal histology performed after 5 days. EGCG/AA NPs were significantly more effective than free EGCG in reducing motor disturbances and depression-like behavior associated with 3-nitropropionic acid toxicity. EGCG/AA NPs treatment also mitigated neuroinflammation and prevented neuronal loss. NP encapsulation enhances therapeutic robustness of EGCG in this model of HD symptomatology. Together with our previous findings, this highlights the potential of EGCG/AA NPs in the symptomatic treatment of neurodegenerative diseases.
比较游离态和纳米颗粒（NP）包裹表没食子儿茶素没食子酸酯（EGCG）治疗类似亨廷顿病（HD）的症状在小鼠。EGCG 被包裹在聚乙二醇化聚乳酸-共-羟基乙酸酸 NPs 中，并用抗坏血酸（AA）。HD 样纹状体损伤和运动障碍通过 3-硝基丙酸中毒诱导小鼠。在 5 天后，共同给予 EGCG 和 EGCG/AA NPs，并进行行为运动评估和纹状体组织学。EGCG/AA NPs 比游离态 EGCG 更有效地减少与 3-硝基丙酸毒性相关的运动障碍和抑郁样行为。EGCG/AA NPs 治疗还减轻了神经炎症并防止了神经元丢失。NP 包封增强了 EGCG 在这种 HD 症状模型中的治疗效果。结合我们之前的研究结果，这突出了 EGCG/AA NPs 在神经退行性疾病症状治疗中的潜力。
